MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

Core Insights - MetaVia Inc. has developed a robust global patent portfolio for its lead asset DA-1726, which is a dual agonist for treating obesity and metabolic disorders, with protection extending to 2041 [1] - The company has 39 granted and pending patents in the U.S. and internationally, covering the unique peptide structure and therapeutic use of DA-1726 [1] - Recent clinical data indicate that DA-1726 at a 48 mg dose resulted in approximately 9% weight loss, significant waist size reduction, and improvements in blood sugar levels, all with a favorable safety profile [1] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [1] - The company is developing DA-1726 for obesity treatment and vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [1] - DA-1726 is designed to be administered once weekly subcutaneously and functions as a dual agonist of GLP-1 and glucagon receptors [1] Product Development - DA-1726 has shown best-in-class potential in pre-clinical studies, outperforming semaglutide in weight loss while allowing for greater food intake [1] - The Phase 1 multiple ascending dose trial demonstrated significant potential for weight loss, glucose control, and waist circumference reduction [1] - Planned 16-week titration studies to 48 mg and 64 mg are expected to yield results in Q4 2026, reflecting confidence in the therapy's tolerability [1]